Clinical Trial Update: Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating veliparib in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• Veliparib (veliparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 2 | Status: COMPLETED | Results posted: 2019-03-19